Kidney health in people with cystic fibrosis on new treatments
Part of Digestive system, Genetic & congenital, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study looks at how the kidneys work in people with cystic fibrosis, especially those taking highly effective new treatments. It aims to understand kidney function in different groups, including those who are hospitalized frequently or rarely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis
- You are over 30 years old (or over 7 if you are often hospitalized)
- You can give your own permission to join the study
- You have not had an organ transplant or cancer
- You are not pregnant or breastfeeding
- You are not on dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how long-term diabetes affects people with cystic fibrosis. It helps researchers understand complications and improve care.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
This study looks at how cystic fibrosis and gene modulator treatments affect the health of your heart and blood vessels. By joining, you'll help researchers understand these effects and potentially improve care for people with CF.
This study looks at new, advanced tests to help doctors better diagnose cystic fibrosis in people whose current test results are not clear. Participation involves a rectal biopsy, which helps researchers study how the CFTR protein works in the body.
This study checks how a common cystic fibrosis (CF) medicine affects urine markers after briefly stopping it and then restarting. The goal is to better understand whether the treatment shift changes kidney-related signals in people with CF.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.